Format

Send to

Choose Destination
Expert Opin Investig Drugs. 2006 Mar;15(3):211-26.

Recent developments in antibacterial drug discovery: microbe-derived natural products--from collection to the clinic.

Author information

1
Infectious Diseases Area, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA. jennifer.leeds@novartis.com

Abstract

The pharmaceutical industry has historically relied on nature to provide compounds for antibacterial drug discovery. In recent years, several pharmaceutical companies have scaled back their efforts in natural product research. Nevertheless, the screening of natural products for antibacterial activity continues to provide excellent sources of biologically and chemically informative leads for new drugs. New technologies in high-throughput cultivation, genetic approaches to biodiversity and discovery of relatively untapped sources of natural products are expanding the ability to find novel, potent and highly selective antibacterial structures. Advances in purification, dereplication and structure elucidation, combined with the ability to chemically or biologically derivatise hits, aim to make the timeline for natural product-derived drug discovery similar or shorter than that expected for small synthetic molecules. This review addresses the strengths and shortcomings of technologies focused on microbe-derived natural products for antibacterial drug discovery and stresses the need for commitment to these approaches in order to achieve the goal of delivering safe, efficacious and high-quality medicines in the long run.

PMID:
16503759
DOI:
10.1517/13543784.15.3.211
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center